Hospital Memorial Arcoverde, Arcoverde, Pernambuco, Brazil.
Universidade Luterana do Brasil, Programa de Pós-Graduação em Biologia Celular e Molecular Aplicada à Saúde, Canoas, Rio Grande do Sul, Brazil.
Eur J Hum Genet. 2022 Jul;30(7):818-823. doi: 10.1038/s41431-022-01098-7. Epub 2022 May 9.
Hereditary cancer risk syndromes are caused by germline variants, commonly in tumor suppressor genes. Most studies on hereditary cancer have been conducted in white populations. We report the largest study in Brazilian individuals with multiple ethnicities. We genotyped 1682 individuals from all country regions with Next-generation sequencing (NGS) panels. Most were women with a personal/family history of cancer, mostly breast and ovarian. We identified 321 pathogenic/likely pathogenic (P/LP) variants in 305 people (18.1%) distributed among 32 genes. Most were on BRCA1 and BRCA2 (129 patients, 26.2% and 14.3% of all P/LP, respectively), MUTYH (42 monoallelic patients, 13.1%), PALB2 (25, 7.8%), Lynch syndrome genes (17, 5.3%), and TP53 (17, 5.3%). Transheterozygosity prevalence in our sample was 0.89% (15/1682). BRCA1/BRCA2 double heterozygosity rate was 0.78% (1/129) for BRCA variants carriers and 0.06% (1/1682) overall. We evaluated the performance of the genetic testing criteria by NCCN and the Brazilian National Health Agency (ANS). The inclusion criteria currently used in Brazil fail to identify 17%-25% of carriers of P/LP variants in hereditary cancer genes. Our results add knowledge on the Brazilian spectrum of cancer risk germline variants, demonstrate that large multigene panels have high positivity rates, and indicate that Brazilian inclusion criteria for genetic testing should be improved.
遗传性癌症风险综合征是由种系变异引起的,通常发生在肿瘤抑制基因中。大多数遗传性癌症的研究都是在白种人群中进行的。我们报告了在具有多种族裔的巴西个体中进行的最大规模研究。我们使用下一代测序 (NGS) 面板对来自全国所有地区的 1682 个人进行了基因分型。大多数是有个人/家族癌症史的女性,主要是乳腺癌和卵巢癌。我们在 305 个人中发现了 321 个致病性/可能致病性 (P/LP) 变体,分布在 32 个基因中。大多数是 BRCA1 和 BRCA2(129 名患者,分别占所有 P/LP 的 26.2%和 14.3%)、MUTYH(42 名单等位基因患者,13.1%)、PALB2(25 名,7.8%)、Lynch 综合征基因(17 名,5.3%)和 TP53(17 名,5.3%)。我们样本中的 Transheterozygosity 患病率为 0.89%(15/1682)。BRCA1/BRCA2 双杂合率在 BRCA 变体携带者中为 0.78%(1/129),在所有患者中为 0.06%(1/1682)。我们评估了 NCCN 和巴西国家卫生署 (ANS) 的遗传检测标准的性能。巴西目前使用的纳入标准未能识别出 17%-25%的遗传性癌症基因 P/LP 变体携带者。我们的结果增加了对巴西癌症风险种系变体谱的了解,表明大型多基因面板具有较高的阳性率,并表明巴西的遗传检测纳入标准需要改进。